Agile Therapeutics (AGRX) remains on track to launch their flagship, Twirla, a once-a-week contraceptive patch. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. (Nasdaq: AGRX), a women’s healthcare company. (AGRX) más recientes en el foro de Yahoo Finanzas. needs of today’s women. Twirla is a combined hormonal contraceptive, or CHC, patch that contains the active ingredients. is a healthcare company, which engages in the development and commercialization of transdermal patch. stock Listing Status: ✅. The Phase 3 SECURE study by AGRX was a multi-center, single-arm, open-lable, 13 cycle trial that was designed to evaluate the efficacy, safety and tolerability of AG200-15, also known as Twirla. Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE) PRINCETON, N. Die letzten Diskussionen über Agile Therapeutics, Inc. Its lead product candidate is known as Twirla and it is a once-weekly prescription contraceptive patch. Agile Therapeutics Receiveable Turnover 2013-2020 | AGRX. Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®. Our current product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. 35 set on Mar 12, 2020. 3JVRqsJZ1iL9He1aGrx1wY3h6MXSsCJ4Q2. As it stands, the plan to launch Twirla in Q4 still. Wainwright gave Agile Therapeutics (NASDAQ: AGRX) a Buy rating last month, the company received another Buy, this time from Maxim Group. However, right now the technical chart looks impressive. AGRX - Agile Therapeutics Inc. the Twirla new drug application, or NDA, and requires us to conduct additional studies or reformulate Twirla to address the concerns raised in the 2017 CRL; • our ability to resubmit the Twirla NDA and obtain and maintain regulatory approval of our product candidates, and the labeling under any approval we may obtain;. The micro-cap biotech that focuses on women's health said late. (Nasdaq: AGRX), a women’s healthcare company, today announced that the U. AGRX), a women's. 1 Agile Therapeutics Presents Additional Twirla® Phase 3 SECURE Study Results at NAFFP 2017 Detailed Bleeding. At the moment the Agile Therapeutics announces peer-reviewed publication of late-stage study for Twirla contraception patch. Food and Drug Administration (FDA) has approved Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system. RPA assay design. b5setsubic51db50abhp-f46rum-hr. - Stock Price Quote and News. The stock is moving within a wide and horizontal trend and further movements within this trend can be expected. AGRX has closed above bottom band by 24. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. View detailed financial information, real-time news, videos, quotes and analysis on Agile Therapeutics, Inc. Made from Flexible Thermoplastic Polyurethane (TPU) and IMD (In-Mould-Decoration) Technology, If you are unsure of the size of your ukulele, Grey Umbra Twirla 2. According to TipRanks. 2021-01-18 07:22. This extension comes about a week after Twirla. Twirla ® is a new non-daily, non-invasive contraceptive approved in the U. , June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. is a healthcare. View the latest AGRX stock quote and chart on MSN Money. Find the latest Agile Therapeutics, Inc. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed. FDA Briefing Docs Crush Agile Therapeutics Stock and Create New Concerns for Twirla Posted on October 28, 2019 by Medtech [y] Staff Investors woke up to a kick in the nuts this morning after Agile Therapeutics (NASDAQ:AGRX) announced their third quarter results and the FDA released the briefing documents for the AdCom meeting on October 30, 2019. 07, 2020 (G. See charts, data and financials for Agile Therapeutics Inc AGRX. (AGRX) has confirmed its plans to resubmit its NDA for Twirla, an investigational low-dose combined hormonal c. 00 and gave the stock a buy rating […]. , , a women's healthcare company, today announced the presentation of additional results from the Phase 3 SECURE trial of its investigational low-dose combination hormonal. 9 Million in Cash, Cash Equivalents, and Marketable Securities as of September 30, 2020 Management to Host Conference Call today at 4:30 PM ET PRINCETON, N. (AGRX) is developing Twirla®, a once-weekly low–dose combination hormonal ted three Phase 3 complete response letter (CRL) in response to the company’s new drug application (NDA) for Twirla®. Twirla, or AG200-15, is Agile's investigational, once-weekly combined hormonal contraceptive patch containing a type of estrogen and a type of progestin as active ingredients. Each TWIRLA treatment cycle is packaged in a carton containing three (3) individually pouched transdermal systems. Agile Therapeutics (NASDAQ: AGRX) is a women's healthcare company in the process of getting their lead product candidate, Twirla, cleared through the FDA, which could happen before the end of 2019. com - December 12 at 3:39 PM: Agile Therapeutics: Managing A Position Ahead Of Twirla's Launch seekingalpha. Dive deeper with interactive charts and top stories of AGILE THERAPEUTICS, INC. (Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2020 financial results after the market close on Thursday, November 12, 2020. 53 on Monday after the women's health specialty pharmaceutical company announced a new patent for Twirla. AGRX - key executives, insider trading, ownership, revenue and average growth rates. Lee los debates de acciones de Agile Therapeutics, Inc. The declines… Read More » Agile Therapeutics (AGRX) Stock Is Nothing Without Twirla. I'm thinking Agile is planning to increase their goal of 85% formulary access within 6 months from now. is a healthcare company, which engages in the development and commercialization of transdermal patch. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane® Feb-07-19 08:00AM: Agile Therapeutics to Present at the 2019 BIO CEO and Investor Conference. Over the past few trading sessions, Agile Therapeutics has given up more than half of its value. Latest Story: Agile Therapeutics to Participate in Fireside Chat at the H. iyi çalışmalar. The Princeton, New Jersey-based company has hired healthcare veteran Kimberly Whelan to take the role of vice president of market access, it announced Thursday. Agile Therapeutics, Inc. Given the current horizontal trend, you can expect Agile Therapeutics stock with a 90% probability to be traded between $2. The Company is focused in the development and commercialization of prescription contraceptive products. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Current Market Cap = $246 million. 10/15/2020 Form EFFECT AGILE THERAPEUTICS INC. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. com Agile Therapeutics, Inc. Feb-11-19 07:30AM : Agile Therapeutics, Inc. Twirla is now available in the United States by prescription for women of reproductive potential with a body mass index (BMI) <30 kg/m2 for whom a combined hormonal contraceptive is appropriate to. The brokerage currently has a buy rating on. swirla twirla's best boards. 405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive. Thestockmarketwatch. (AGRX) stock discussions in Yahoo Finance's forum. Agile Therapeutics Inc (NASDAQ:AGRX) CEO Al Altomari sat down with Proactive Investors at the BIO CEO and Investor Conference in New York. Feb-11-19 07:30AM : Agile Therapeutics, Inc. Agile Therapeutics, Inc. apart for that it is well developing a right flow of twirla line and other contraceptive products such AG200- ER. Agile Therapeutics Inc. The Company�s lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch in Phase III clinical development. … - twitter. , June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. AGRX's market cap is 260. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. This model is highly dependent upon Twirla attaining regulatory approval and its commercial success and will be. 09/22/20 H. Agile Therapeutics (NASDAQ:AGRX) CEO Al Altomari sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. AGRX: Positive Results for Twirla® Adhesion Study; NDA Resubmission in 2Q19. Check out TwirLa's art on DeviantArt. 12-07 globenewswire. 08, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Several other research firms have also recently issued reports on AGRX. In depth view into AGRX (Agile Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. 04 on Wednesday, hitting $2. For more information, please visit the company. As long as Twirla delivers certain amount of hormone consistently into the body, it should work as planned. The stock is moving within a wide and horizontal trend and further movements within this trend can be expected. Trovagene is a clinical-stage oncology therapeutics company. 1 Agile Therapeutics (AGRX) 39th Annual J. AGRX stock has a five-year performance of -64. AGILE THERAPEUTICS: to Host Third Quarter 2020 Financial Results Conference Call and Provide Corporate and Twirla® Commercial Updates on Thursday, November 12, 2020 AQ 11/04. AGRX - Agile Therapeutics, Inc. News: No news. US:AGRX / Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months and year ended. 2021-01-18 07:22. Agile Therapeutics. 16 Pdufa to Twirla AGRX ended 3Q with $18. Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE). The Phase 3 SECURE study by AGRX was a multi-center, single-arm, open-lable, 13 cycle trial that was designed to evaluate the efficacy, safety and tolerability of AG200-15, also known as Twirla. Johnson and Johnson (JNJ)) to buy them out and be able to market the product more effectively given their larger. Agile Therapeutics, Inc. Analyst Jason McCarthy assigned a Buy rating to Agile Therapeutics yesterday and set a price target of $8. Agile Therapeutics, Inc. Twirla is designed for weekly application to deliver a 30 mcg daily dose of ethinyl estradiol, a type of estrogen, along with a 120 mcg daily dose of levonorgestrel, a well-known progestin with a. Find the latest Agile Therapeutics, Inc. @gcassidy718 $AGRX reasonable changes in stock price 2. GuruFocus Articles Total 2. $AGRX Agile Therapeutics announced nationwide commercial launch and availability of Twirla transdermal system, a new non-daily, non-invasive contraceptive patch. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. It is as effective, if not more, as oral contraceptive ("The Pill"). (AGRX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their compensation. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. 1% and a 43. Agile Therapeutics stock quote and AGRX charts. On Wednesday, the AdCom review caused a major upset, with a 14-1 vote in favor of supporting Twirla for approval. Agile Therapeutics Inc (NASDAQ:AGRX) CEO Al Altomari tells Proactive Investors the FDA has accepted for review its new drug application resubmission for Twirla, its low-dose combined hormonal contraceptive patch. 67 Billion Market Cap. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. It has also developed a proprietary technology called Skinfusion. 1BmqtsE7oh8vodFZRxst2sU13kf38GU5XK. The Agile (NASDAQ: AGRX) product, called Twirla, deliver delivers a combination of hormones via a proprietary skin patch applied once a week. Twirla is designed for weekly application to deliver a 30 mcg daily dose of ethinyl estradiol, a type of estrogen, along with a 120 mcg daily dose of levonorgestrel, a well-known progestin with a. Find the latest Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. Learn about AGRX (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. - Stock Price Quote and News. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch. AGRX is down today, but where's it headed in this surging post-election market?. As a result, it allows women to extend the overall length is AG200-SP. Calendar of FDA public advisory committee meetings. At just $68 million in market capitalization, Agile Therapeutics (AGRX) is anything but what you'd call "Big Pharma" -- but it's getting bigger. 97 following a significant upgrade from analysts at Suntrust, which increased their price target from $24 to $150. Agile Therapeutics, Inc. Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings data on Tuesday, November 17th. Agile Therapeutics (NASDAQ:AGRX) This penny stock has endured its fair share of ups and downs since debuting on the Nasdaq back in 2014. (AGRX) Aktien im Forum von Yahoo Finanzen finden. , a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. 67 Billion Market Cap. Top trades and best-performing strategies with Agile Therapeutics, Inc. PRINCETON, NJ, USA I February 14, 2020 I Agile Therapeutics, Inc. Agile Therapeutics (Nasdaq: AGRX) Announces Favorable Outcome of FDA Advisory Committee Meeting The committee voted 14 to 1, with 1 abstension, to favor of approval of its investigational contraceptive patch, Twirla ® (AG200-15) Mayne Pharma (ASX: MYX) Signs Exclusive License and Supply Agreement with Mithra for Estelle ® in the United States. Twirla is based on our proprietary transdermal patch technology, called Skinfusion ®, which is designed to allow drug delivery through the skin. The Company is focused in the development and commercialization of prescription contraceptive products. stock Listing Status: ✅. , May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Back to AGRX Overview NASDAQ, Inc. Food and Drug. On January 3, 2017, Agile Therapeutics Inc (NASDAQ: AGRX) announced top-line results from its Phase 3 SECURE clinical trial of Twirla®, its investigational low-dose combined hormonal contraceptive patch. The bloodshed started when the company issued its most recent quarterly report. Its primary candidate, AG200-15, which it plans on marketing as Twirla, is a prescription contraceptive patch designed for once-weekly use. Learn how to read stock charts and identify technical patterns as ClayTrader does a quick stock chart review on Agile Therapeutics, Inc (AGRX). This is the main Agile Thrpe stock chart and current price. AGILE THERAPEUTICS INC ExhibitEX-99. , a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Agile Therapeutics (NASDAQ:AGRX) has announced it has resubmitted to the US Food and Drug Administration (FDA) its new drug application for its lead product candidate, Twirla. Agile Therapeutics Inc. This model is highly dependent upon Twirla attaining regulatory approval and its commercial success and will be. Food and Drug Administration has refused to approve Agile Therapeutics Inc (NASDAQ: AGRX)’ Twirla, a low-dose contraceptive patch said to offer more convenience compared to birth control pills and which is also reputed to have a better safety profile compared to other patches. commercial launch of Twirla® (levonorgestrel and ethinyl estradiol) transdermal. Agile Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Provide Corporate and Twirla® Commercial Updates on Thursday, November 12, 2020 November 04, 2020 From GlobeNewswire News Releases. is a women's health specialty pharmaceutical company. Its lead product candidate, Twirla, also known as AG200-15, is an. According to TipRanks. Bollinger Bands are 52. Agile will be allowed to make interest-only payments until February 2023. Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE) PRINCETON, N. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed. (NASDAQ:AGRX) | Seeking Alpha 2019-11-06 seekingalpha. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly HTML Code (Click to Copy). On Wednesday, the AdCom review caused a major upset, with a 14-1 vote in favor of supporting Twirla for approval. Filter AGRX News Items. $AGRX Now that TWIRLA is FDA Approved and its only competitor XULANE by Mylan Pharm $MYL is sub par to TWIRLA. Umbra Twirla Abfalleimer Schwingdeckel Kosmetikeimer Papierkorb Weiß PP 9 L NEU. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. The fund is Perceptive Advisors, […]. Oppenheimer analyst Leland Gershell assigned a Buy rating to Agile Therapeutics (AGRX – Research Report) today and set a price target of $12. Agile's product candidates are designed to provide women. Twirla is based on the company’ proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. View company web site for more details. after resubmitting a New Drug Application (NDA) for Twirla on May 16, 2019. It is focused on the development and commercialization of new prescription contraceptive products. 3JVRqsJZ1iL9He1aGrx1wY3h6MXSsCJ4Q2. commercial launch of Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive. 's (AGRX) New Drug Application for Twirla, an investigational low-dose combined hormonal contraceptive patch, has been accepted for review by the FDA - with a decision date. Start Investing The Best Online Stock Trading Brokers. Agile Therapeutics Share Price and News. Twirla, which earned FDA approval in early 2020, is worn weekly and delivers daily doses of estrogen Agile Therapeutics, Inc - AGRX Stock Chart Technical Analysis for 11-15-19. Food and Drug Administration (FDA) the NDA for its lead product candidate, Twirla®, an investigational low-dose combined hormonal. AGRX Stock Quote - Agile Therapeutics, Inc. Meinungen austauschen und die Ansichten von Aktienhändlern und Investoren erfahren. The stock is moving within a wide and horizontal trend and further movements within this trend can be expected. 2%, which took the trading range below the 3-day low of $2. commercial launch of Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch. New Jersey-based Agile is focused on seeking FDA approval of its lead drug Twirla, and is looking forward to its Feb 16 PDUFA date. This should help with the patients without formulary access for their first 6 months. View detailed AGRX description & address. 00014077 LTC. (NASDAQ:AGRX), a women's healthcare company, today announced that it will host a virtual Investor/Analyst Day on Monday, September 21, 2020 from 11:00. Twirla is based on its transdermal patch technology, called Skinfusion, which is designed to provide advantages over available patches and is intended to optimize patch adherence and. The specialty pharmaceutical company reported ($0. Its product candidates are designed to provide women with contraceptive options. 10/15/2020 Form EFFECT AGILE THERAPEUTICS INC. Assuming the comparative adhesion study completes in the first quarter of 2019, we believe Agile will be able to resubmit the NDA for Twirla® in the second quarter of 2019. RPA assay design. , (NASDAQ: AGRX), a women's healthcare company, today announced additional data from its Phase 3 SECURE trial of Twirla ® (AG200-15), an investigational, once-weekly, low-dose hormonal contraceptive patch, which showed women experienced mean decreases in length of bleeding and spotting episodes. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials. Calendar of FDA public advisory committee meetings. Get up-to-the-second AGILE THERAPEUTICS, INC. (Nasdaq: AGRX), a women’s healthcare company, today announced the U. Track performance, allocation, dividends, and risks. Twirla is now available in the United States by prescription for women of reproductive potential with a body mass index (BMI) <30 kg/m2 for whom a combined hormonal contraceptive is appropriate to. 2021-01-18 07:22. Thank you! Your email has been. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. $AGRX Announces Commercial Launch of #Twirla® (levonorgestrel and ethinyl estradiol) transdermal system. com Company to Present Twirla ® Commercial Plan. Agile Therapeutics Receiveable Turnover 2013-2020 | AGRX. 3Byb7YBER4gKFwNqjUEwMVR2pp4WZ6kJJ60. Twirla: Its Competition and Product Differentiation: Twirla was approved by the FDA on February - AGRX has other drugs in its pipeline (Phase 1 and 2) using the same patented patch technology with. Agile Therapeutics Inc. b5setsubic51db50abhp-f46rum-hr. 35 set on Mar 12, 2020. Twirla is. Three analysts have made estimates for Agile Therapeutics’ earnings, with the highest sales estimate coming in at $1. AGRX has stated in previous earnings calls that it plans to begin production of Twirla in Q4 of this year. 97 following a significant upgrade from analysts at Suntrust, which increased their price target from $24 to $150. Agile Therapeutics Inc (NASDAQ: AGRX) shares are advancing Tuesday after the company announced clinching of a term loan facility. New Jersey-based Agile is focused on seeking FDA approval of its lead drug Twirla, and is looking forward to its Feb 16 PDUFA date. Lateral flow consumables. In a report released today, Randall Stanicky from RBC Capital reiterated a Buy rating on Agile Therapeutics (AGRX – Research Report), with a price target of $8. $AGRX Check out twirla. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will participate in a fireside chat at the H. Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl estradiol) GlobeNewswire Inc. Achetez LOFT TWIRLA CAN 9L BRONZE à Walmart Canada. Latest Trade. (AGRX) is developing Twirla®, a once-weekly low–dose combination hormonal ted three Phase 3 complete response letter (CRL) in response to the company’s new drug application (NDA) for Twirla®. The stock is moving within a wide and horizontal trend and further movements within this trend can be expected. AGRX is down today, but where's it headed in this surging post-election market?. Continue Reading BRIEF-Agile Therapeutics To Join. Agile Therapeutics (AGRX) recently announced that the FDA decided to extend Twirla’s PDUFA goal date from November 16th to February 16th, 2020. The hormone combination in Twirla has a long history of use in birth control pills. (Nasdaq: AGRX), a women’s healthcare company, today announced the U. Agile Therapeutics, Inc. Twirla® (ethinyl estradiol and levonorgestrel). The treatment is a clinical-stage low-dose contraceptive patch that the company hopes to get approved by the FDA. AGRX's market cap is 260. The study, which was initiated at the request of the FDA, comes after the FDA rejected Agile's initial marketing application back in 2013. The firm is […]. Agile Therapeutics. Die letzten Diskussionen über Agile Therapeutics, Inc. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of Twirla® (levonorgestrel/ethinyl estradiol) transdermal. is a healthcare company, which engages in the development and commercialization of transdermal patch. $AGRX Announces Commercial Launch of #Twirla® (levonorgestrel and ethinyl estradiol) transdermal system. Food and Drug Administration (FDA) the NDA for its lead product candidate, Twirla ®, an investigational low-dose combined hormonal contraceptive patch (AG200-15). Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. Oppenheimer analyst Leland Gershell assigned a Buy rating to Agile Therapeutics (AGRX – Research Report) today and set a price target of $12. 1,800,000 Twirla customers at $124 a month is $2,678,400,400 Billion dollars a year in sales. (NASDAQ: BTAI) shares closed up 55% to $36. Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System in Contraception Nov 23 Agile Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference. , a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Корзина для мусора с крышкой Twirla 9 л черная. (Nasdaq: AGRX), a women’s healthcare company, today announced it has resubmitted to the U. Agile Therapeutics, Inc. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. View the latest AGRX stock quote and chart on MSN Money. Agile Therapeutics (AGRX) soared to a 52-week high of $12. Agile Therapeutics started at outperform with $5 stock price target at Oppenheimer MarketWatch. GbHDAYH8aGrX9wXsC5B6wimG5BzwGahnMV0. It has also developed a proprietary technology called Skinfusion. agrx The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230. I expect an anticipatory run up of AGRX stock as we get closer and closer to Q4, and once Twirla hits the market I believe share prices have the ability to exceed a gain 100% +. 2% success rate. Die letzten Diskussionen über Agile Therapeutics, Inc. com, Stanicky is ranked 0 out of 5 stars with an average return of -21. is a healthcare company, which engages in the development and commercialization of transdermal patch. ValuEngine upgraded shares of Agile Therapeutics (NASDAQ:AGRX) from a hold rating to a buy rating in a report released on Tuesday morning, ValuEngine reports. PRINCETON, NJ, USA I February 14, 2020 I Agile Therapeutics, Inc. Twirla now has a green light from the FDA. the Twirla new drug application, or NDA, and requires us to conduct additional studies or reformulate Twirla to address the concerns raised in the 2017 CRL; • our ability to resubmit the Twirla NDA and obtain and maintain regulatory approval of our product candidates, and the labeling under any approval we may obtain;. This is the main Agile Thrpe stock chart and current price. In general, investors are looking for financial data, but in this case, the big kicker was a note about Twirla. Click Here to get the full Stock Score Report on Agile Therapeutics Inc (AGRX) Stock. 53 on Monday after the women's health specialty pharmaceutical company announced a new patent for Twirla. 18) EPS for the quarter, meeting analysts. Agile Therapeutics, Inc. Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE) PRINCETON, N. (Nasdaq: AGRX), a women’s healthcare company, today announced that the U. 441R314AGRX. Twirla is based on its transdermal patch technology, called Skinfusion, which is designed to provide advantages over available patches and is intended to optimize patch adherence and stability and. Lugo covers the Healthcare sector, focusing on stocks such as. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. It is one of the leading companies in the part of the Twrila, and it called AG200- to 15. Agile Therapeutics: Billion Dollar Buy-Out Is On The HorizonMay 01, 2020 8:45 AM ETAgile Therapeutics, Inc. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Agile resubmitted the NDA in response to a February 2013 Complete Response Letter (CRL) from the FDA, which recommended that Agile conduct a new clinical trial. Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE). $AGRX Announces Commercial Launch of #Twirla® (levonorgestrel and ethinyl estradiol) transdermal system. * agile therapeutics, inc. Agile resubmitted the NDA in response to a December 2017 Complete Response Letter (CRL) from the FDA. Agile Therapeutics (AGRX) soared to a 52-week high of $12. Agile Therapeutics, Inc. established a wholesale acquisition cost of $159. Click Here to get the full Stock Score Report on Agile Therapeutics Inc (AGRX) Stock. The Company�s lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch in Phase III clinical development. , a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Twirla ® is a new non-daily, non-invasive contraceptive approved in the U. 1% and a 43. Agile Therapeutics Q3 Loss Meets Street Views, Plans to Launch Twirla By Year-End -- Stock 1% Lower After-Hours 5:18PM ET 11/12/2020 MT Newswires. Latest Trade. AGRX - key executives, insider trading, ownership, revenue and average growth rates. This model is ® attaining regulatory approval and its commercial success and will be. (NASDAQ:AGRX) | Seeking Alpha 2019-11-06 seekingalpha. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. AGRX: FDA Provides Path to NDA Resubmission for Twirla®… Based on our probability adjusted DCF model that takes into account potential future revenues from Twirla®, AGRX is valued at $2. AGRX News and Headlines - Agile Therapeutics Inc. Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®. Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE) PRINCETON, N. At just $68 million in market capitalization, Agile Therapeutics (AGRX) is anything but what you'd call "Big Pharma" -- but it's getting bigger. b5setsubic51db50abhp-f46rum-hr. GbHDAYH8aGrX9wXsC5B6wimG5BzwGahnMV0. 36/shr on a stand-alone basis. アジャイル・セラピューティクス【agrx】の株価。nyse(ニューヨーク証券取引所)とnasdaqに上場している全銘柄の株価やチャート、業績などを網羅。. 70% above the 52 week low of 1. Find out why Agile Therapeutics's (AGRX) news sentiment is more negative in relation to stocks in the Healthcare sector. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. (AGRX) had a good day on the market for Monday May 11 as shares jumped 10. Agile therapeutics inc. Each TWIRLA treatment cycle is packaged in a carton containing three (3) individually pouched transdermal systems. is a healthcare company, which engages in the development and commercialization of transdermal patch. Agile Therapeutics Announces Nationwide 12/07/20 Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE) PRINCETON, N. 1BmqtsE7oh8vodFZRxst2sU13kf38GU5XK. On January 3, 2017, Agile Therapeutics Inc (NASDAQ: AGRX) announced top-line results from its Phase 3 SECURE clinical trial of Twirla®, its investigational low-dose combined hormonal contraceptive patch. com - December 12 at 3:39 PM: Agile Therapeutics: Managing A Position Ahead Of Twirla's Launch seekingalpha. Twirla is less invasive than rings. Agile Therapeutics Inc. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. b5setsubic51db50abhp-f46rum-hr. Snapshot:AGRX. Twirla Product Co-development Program Future revenue growth driver Agile (AGRX) contraceptive patch Exclusive manufacturer Delivers low dose of contraceptive hormones Agile indicating potential. Twirla: Its Competition and Product Differentiation: Twirla was approved by the FDA on February - AGRX has other drugs in its pipeline (Phase 1 and 2) using the same patented patch technology with. Company Name: Agile Therapeutics Inc. that rank is chiefly influenced by a fundamental score of 96. PRINCETON, NJ, November 14, 2019 Agile Therapeutics, Inc. Agile Therapeutics | LinkedIn‘de 1. 1 Exhibit 99. (Nasdaq: AGRX), a women’s healthcare company, today announced the U. Our current product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. AGRX - Agile Therapeutics, Inc. In a report released today, Randall Stanicky from RBC Capital reiterated a Buy rating on Agile Therapeutics (AGRX – Research Report), with a price target of $8. Twirla is now available in the United States by prescription for women of reproductive potential with a body mass index (BMI) <30 kg/m2 for whom a combined hormonal contraceptive is appropriate to. Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Our lead product candidate, Twirla , also known as AG200-15, is a once-weekly prescription combination. “We are very pleased that BRUDAC voted in favor of Twirla. 8%) resubmits its New Drug Application (NDA) to the FDA seeking approval of lead product candidate Twirla, a low-dose combined hormonal contraceptive patch. (Nasdaq: AGRX), a women's Healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will participate in a fireside chat at the H. New Jersey-based Agile is focused on seeking FDA approval of its lead drug Twirla, and is looking forward to its Feb 16 PDUFA date. 07, 2020 (G. Last Price $2. Agile Therapeutics, Inc. 97 following a significant upgrade from analysts at Suntrust, which increased their price target from $24 to $150. We believe there is an unmet market need for a low-dose contraceptive patch, which is designed to increase patient convenience and compliance in a non-invasive fashion. plunged over 47% on Friday after the Company's investigational low-dose combined hormonal contraceptive patch Twirla was turned down by the FDA yet again. I see this stock at least doubling in the next few months as they launch their new and only FDA approved product (planned for Q4 2020): Twirla (a female contraceptive patch). I see this stock at least doubling in the next few months as they launch their new and only FDA approved product (planned for Q4 2020): Twirla (a female contraceptive patch). 00 price objective on shares […]. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. 67 million shares traded hands on 9,068 trades for the day,. This is a sign that the market may be about to initiate a new trend. Twirla is based on our proprietary transdermal patch technology, called Skinfusion ®, which is designed to allow drug delivery through the skin. 52, down 47. (Nasdaq: AGRX), a women’s healthcare company, today announced the U. commercial launch of Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, a new. When this moves it will be fast and frantic. 7% per year. 2-GALLON (9L) Capacity: At 10 x 8 x 14 inches, TWIRLA works with both 3-gal or 4-gal garbage. The company’s shares closed last Friday at $2. AGRX: FDA Provides Path to NDA Resubmission for Twirla®… Based on our probability adjusted DCF model that takes into account potential future revenues from Twirla®, AGRX is valued at $2. AGRX Stock Has Given Up More Than Half Of Its Value. The company’s shares closed last Monday at $3. 01572198 BTG. Agile Therapeutics (AGRX) Fair Value Target Raised to $9 at Janney. (AGRX) Aktien im Forum von Yahoo Finanzen finden. 4 Gallon, Black: Home & Kitchen. 's pipeline consists of two classes of product candidates: Twirla line extensions and other transdermal contraceptive product candidates, including AG200-ER, AG200-SP, AG200-ER, and AG890. The company has a quick ratio of 10. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. 1 Exhibit 99. $AGRX Check out twirla. Short interest data is reported on mid-month and end-of-month settlement. Lateral flow consumables. Its lead product candidate, Twirla, also known as AG200-15, is an. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. The specialty pharmaceutical company reported ($0. com: Umbra Twirla Trash Can with Swing-top Lid, 2. The Company has completed its Phase 3 clinical trials of Twirla and is pursuing regulatory approval in the U. 86 at 09:38 GMT Dec 01 2020 Key statistics On Tuesday, Agile Therapeutics Inc (AGRX:NAQ) closed at 2. Get up-to-the-second AGILE THERAPEUTICS, INC. Agile therapeutics (AGRX) has had a, shall we say, crazy week in the market. commercial launch of Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive. Lead product, Twirla contraceptive patch is awaiting for FDA approval on or before February 16. Dive deeper with interactive charts and top stories of AGILE THERAPEUTICS, INC. * agile therapeutics, inc. Check out TwirLa's art on DeviantArt. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. is a women's health specialty pharmaceutical company. Back to AGRX Overview NASDAQ, Inc. Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane® Feb-07-19 08:00AM: Agile Therapeutics to Present at the 2019 BIO CEO and Investor Conference. It is indeed. View Agile Therapeutics, Inc. According to TipRanks. Oppenheimer analyst Leland Gershell assigned a Buy rating to Agile Therapeutics (AGRX – Research Report) today and set a price target of $12. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly HTML Code (Click to Copy). 30, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and. Bollinger Bands are 52. 3AgrX6bDgDhMo9zEHCPc583pKymuUx3Niw0. 43 % change recently https @Carter_Stocks $AGRX chart since the FDA approval in February for Twirla https. Agile Therapeutics cash on hand from 2013 to 2020. In a report released today, Randall Stanicky from RBC Capital reiterated a Buy rating on Agile Therapeutics (AGRX – Research Report), with a price target of $8. - 12/7/2020 7:30:00 AM: Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla® (levonorgestrel and ethin GlobeNewswire Inc. Корзина для мусора с крышкой Twirla 9 л черная. 1FBhckzWjiznPtPHwJbg6AgRX6vzK1St3W. On January 3, 2017, Agile Therapeutics Inc (NASDAQ: AGRX) announced top-line results from its Phase 3 SECURE clinical trial of Twirla®, its investigational low-dose combined hormonal contraceptive patch. 5% and a 18. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. ” The company was incorporated in December 1997 and its activities since inception have consisted principally of “raising capital and performing research and development, including development of the Company’s lead product candidate Twirla®, also known. 91 USD 同社のリード製品候補の「Twirla」はまた「AG200-15」として知られ、複合ホルモン避妊薬(CHC)パッチである。. Twirla is based on our proprietary transdermal patch technology, called Skinfusion ®, which is designed to allow drug delivery through the skin. com Company to Present Twirla ® Commercial Plan. Several other research firms have also recently issued reports on AGRX. 's primary product candidate, Twirla, also known as AG200-15, is a once-weekly prescription combination hormonal contraceptive patch that is at the end of clinical development. Twirla (levonorgestrel/ethinyl estradiol transdermal system) or AG200-15 is an investigational, once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl. Agile Therapeutics (AGRX) soared to a 52-week high of $12. Unfortunately, the bloodshed continues today. Twirla is now available in the United States by prescription for women of reproductive potential with a body mass index (BMI) <30 kg/m2 for whom a combined hormonal contraceptive is appropriate to. (the “Company”) issued a press release announcing that the. 51k following, 25174 Pins. 832,346 shares of the stock traded hands, compared to its average volume of 922,924. 91 USD 同社のリード製品候補の「Twirla」はまた「AG200-15」として知られ、複合ホルモン避妊薬(CHC)パッチである。. Twirla (ethinyl estradiol and levonorgestrel transdermal system) or AG200-15 is an investigational low-dose, once-weekly combined hormonal contraceptive (CHC) patch that contains the active. com) - Agile Therapeutics Inc. Agile Therapeutics (NASDAQ:AGRX) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Thursday, BidAskClub reports. View detailed AGRX description & address. News: No news. Continue Reading BRIEF-Agile Therapeutics To Join. Twirla (ethinyl estradiol and levonorgestrel transdermal system) is a low-dose combined hormonal contraceptive patch for birth control. Agile Therapeutics Inc AGRX:NASDAQ. Includes Twirla side effects, interactions and indications. - AGRX Stock Chart Technical Analysis for 02-11-2020 Subscribe to My MAIN Channel Here: https://www. 35 set on Mar 12, 2020. On Wednesday, the AdCom review caused a major upset, with a 14-1 vote in favor of supporting Twirla for approval. 961 takipçi Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Thestockmarketwatch. The fund is Perceptive Advisors, […]. Do you want to learn more about Twirla? twirla agrx. PRINCETON, N. Twirla® on Track for. Calendar of FDA public advisory committee meetings. Since Twirla’s FDA approval, the company has been working hard to get their product. Given the current horizontal trend, you can expect Agile Therapeutics stock with a 90% probability to be traded between $2. 36/shr on a stand-alone basis. Twirla (levonorgestrel/ethinyl estradiol transdermal system) or AG200-15 is an investigational, once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl. Agile Therapeutics, Inc. Assuming the comparative adhesion study completes in the first quarter of 2019, we believe Agile will be able to resubmit the NDA for Twirla® in the second quarter of 2019. On January 10, 2018, Agile Therapeutics, Inc. The Company has developed a transdermal patch technology, called Skinfusion. @gcassidy718 $AGRX reasonable changes in stock price 2. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch. Twirla (ethinyl estradiol and levonorgestrel transdermal system) is a contraceptive patch used for birth control. Click Here to get the full Stock Score Report on Agile Therapeutics Inc (AGRX) Stock. Friday, December 22, 2017. Our Analysis. , a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. is a healthcare company, which engages in the development and commercialization of transdermal patch. Address : 3JVRqsJZ1iL9He1aGrx1wY3h6MXSsCJ4Q2 file_copy. How Agile Therapeutics (AGRX) Stock Stands Out in a Strong Industry. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Twirla is based on its transdermal patch technology, called Skinfusion, which is designed to provide advantages over available patches and is intended to optimize patch adherence and. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without. The declines… Read More » Agile Therapeutics (AGRX) Stock Is Nothing Without Twirla. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA. cf6_86oldgear6da6867agrx2275-40-19-4. Twirla is designed for weekly application to deliver a 30 mcg daily dose of ethinyl estradiol, a type of estrogen, along with a 120 mcg daily dose of levonorgestrel, a well-known progestin with a. Covering the stock for Oppenheimer, 5-star analyst Leland Gershell points out that during the COVID-19 storm, AGRX hasn’t been sitting idly by. Twirla is a once-a-week transdermal treatment with a combined hormonal approach that delivers a 30 mcg daily dose of ethinyl estradiol (a type of estrogen) and a 120 mcg daily dose of. Learn how to read stock charts and identify technical patterns as ClayTrader does a quick stock chart review on Agile Therapeutics, Inc (AGRX). 04% to close at $2. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. See the company profile for Agile Therapeutics, Inc. Company information: AGRX describes itself as a “healthcare company dedicated to fulfilling the unmet health needs of today’s women. Корзина для мусора с крышкой 9 л Umbra Twirla серый. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive. AGRX News and Headlines - Agile Therapeutics Inc. On January 10, 2018, Agile Therapeutics, Inc. Friday, June 07, 2019. The patch can be worn on the abdomen, buttock, or upper torso (excluding the breasts). El CRL contiene recomendaciones. Brand name: Twirla Generic name: ethinyl estradiol and levonorgestrel Dosage form: Transdermal System Company: Agile Therapeutics, Inc. This model is ® attaining regulatory approval and its commercial success and will be. (NASDAQ:AGRX) | Seeking Alpha 2019-11-06 seekingalpha. Thank you! Your email has been. 09/28/2020 Agile Therapeutics Inc (NASDAQ: AGRX) had its "buy" rating re-affirmed by analysts at William Blair. Agile Therapeuti (NASDAQ:AGRX) traded in a range yesterday that spanned from a low of $2. Agile Therapeutics, Inc. - Stock Price Quote and News. Agile Therapeutics Inc (NASDAQ:AGRX) is gearing up for the commercialization of its lead drug Twirla with some new faces on its executive team. The study failed to meet standards achieved by other. AGRX - key executives, insider trading, ownership, revenue and average growth rates. Stock analysis for Agile Therapeutics Inc (AGRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Agile Therapeutics is a women's healthcare company whose lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. The company’s shares closed last Friday at $2. Simple, clean design: TWIRLA Trash Can has a simple yet effective design that looks great with any 2. This is my prediction for the market cap of AGRX and it’s product Twirla in 3 or so years = $2. On Wednesday, the AdCom review caused a major upset, with a 14-1 vote in favor of supporting Twirla for approval. AGRX investment & stock information. [AGRX] has traded in a range of $0. The Company�s lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch in Phase III clinical development. 10/15/2020 Form EFFECT AGILE THERAPEUTICS INC. PRINCETON, N. (AGRX) stock discussions in Yahoo Finance's forum. Ask anything you want to learn about Ульян by getting answers on ASKfm. 00 and gave the stock a buy rating […]. Less than six weeks ago, Agile’s share price was on the rise following the FDA’s approval of Twirla, the company’s contraceptive patch. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Zacks Small Cap Research +9. , a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. The company's product candidates include Twirla and Progestin. 00 price objective on shares […]. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ. Agile Therapeutics | LinkedIn‘de 1. Announces. Agile Therapeutics Inc (NASDAQ: AGRX) has. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and. Webull offers Agile (AGRX) historical stock prices, in-depth market analysis, NASDAQ: AGRX real-time stock quote data, in-depth charts, and a fully built financial calendar to help you invest smart. that rank is chiefly influenced by a fundamental score of 96. On January 3, 2017, Agile revealed information related to the Phase 3 study of its Twirla product, a combined hormonal contraceptive patch. 2 Gallon Trash Can with. Agile Therapeutics Inc (AGRX). Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE) PRINCETON, N. com - Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl. In a report released today, Randall Stanicky from RBC Capital reiterated a Buy rating on Agile Therapeutics (AGRX – Research Report), with a price target of $8. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. 73 percent on Wednesday, January 27, 2021, on 1. PRINCETON, N. Part of that is the uncertainty of Agile's ability to market and sell the product, but some of that came amid a broad selloff in biotech stocks. Share your opinion and gain insight from other stock traders and investors. Twirla ® is a new non-daily, non-invasive contraceptive approved in the U. , (Nasdaq: AGRX) (Agile or the Company), a forward-thinking women’s healthcare company, today announced that the U. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Annotate, download XLSX & look up similar tables. Twirla is. Food and Drug Administration (FDA) has approved Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system. Its lead product candidate, Twirla, also known as AG200-15, is an. AGRX: Positive Results for Twirla® Adhesion Study; NDA Resubmission in 2Q19: Feb-11-19 07:30AM: Agile Therapeutics, Inc. Agile Therapeutics, Inc. Agile resubmitted the NDA in response to a December 2017 Complete Response Letter (CRL) from the FDA. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company’s shares closed last Monday at $3. AGRX Stock Has Given Up More Than Half Of Its Value. Click to view NAQ:AGRX's StockReport. 37% over the last 12 months, and the average rating from wall street analysts is a strong buy. 08 per share a year earlier, meeting analysts' expectations in. Por último, la CRL cuestiona las propiedades de adhesión in vivo de Twirla y su potencial relación con los resultados de la prueba clínica SECURE fase 3. Food and Drug Administration (FDA) the NDA for its lead product candidate, Twirla ® , an investigational low-dose. , 101 Poor Farm Road, Princeton 08540, United States. Latest Trade. (Nasdaq: AGRX), a women's Healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will participate in a fireside chat at the H. Share your opinion and gain insight from other stock traders and investors. They are both combination products containing an estrogen and progestin, however, the products contain different progestins and have slight differences in their appearance, efficacy and side effects profile. The declines… Read More » Agile Therapeutics (AGRX) Stock Is Nothing Without Twirla. Agile Therapeutics, Inc. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc.